Literature DB >> 27460091

Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.

Gloria Ravegnini1, Margherita Nannini2, Vittorio Simeon3, Muriel Musti4, Giulia Sammarini1, Maristella Saponara2, Lidia Gatto2, Milena Urbini5, Annalisa Astolfi5, Guido Biasco2,5, Maria A Pantaleo2,5, Nicola Venturoli6, Patrizia Hrelia1, Sabrina Angelini7.   

Abstract

DNA repair pathways play an essential role in cancer susceptibility by maintaining genomic integrity. This led us to investigate the influence of polymorphisms in the genes coding repair pathway enzymes on gastrointestinal stromal tumours (GIST) susceptibility, tumour characteristics and clinical outcome. We investigated a panel of 20 polymorphisms in 11 genes in 81 cases and 147 controls. The XPD rs13181 wild-type allele and hOGG1 rs1052133 and XPF rs1800067 minor alleles were significantly associated with disease susceptibility. XPA rs1800975 and rs2808668 were associated with tumour size (P = 0.018), metastatic status at onset (P = 0.035) and mitotic index (P = 0.002). With regards to outcome treatment, the XPD rs50872 minor allele had a significant favourable impact on time to progression (TTP). Similarly, the XPC rs2228000 minor allele was correlated with a longer TTP (P = 0.03). On the contrary, the XPC rs2228001 and hOGG1 rs1052133 minor alleles were associated with a diminished TTP (P = 0.005 and P = 0.01, respectively). Regarding OS, we found the presence of at least one hOGG1 (rs1052133) minor allele that had a 60 % lower risk to die compared to the wild-type carriers (P = 0.04). Furthermore, the XRCC3 rs861539 variant allele is associated with a hazard of early death compared with the wild-type genotype (P = 0.04). To the best of our knowledge, this is the first study on polymorphisms in DNA repair genes, belonging to the different pathways, extensively evaluated in GIST patients. Through this multiple candidate gene approach, we report for the first time the significant associations between polymorphisms in DNA repair genes, susceptibility, clinical pathological features and clinical outcome in GIST.

Entities:  

Keywords:  DNA repair pathways; GIST; Imatinib; Polymorphisms

Mesh:

Substances:

Year:  2016        PMID: 27460091     DOI: 10.1007/s13277-016-5276-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  61 in total

1.  Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.

Authors:  Oleg V Tsodikov; Jacquelin H Enzlin; Orlando D Schärer; Tom Ellenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

2.  Inherited susceptibility to bleomycin-induced micronuclei: correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity.

Authors:  Sabrina Angelini; Rajiv Kumar; Fabio Carbone; Justo Lorenzo Bermejo; Francesca Maffei; Giorgio Cantelli-Forti; Kari Hemminki; Patrizia Hrelia
Journal:  Mutat Res       Date:  2007-09-14       Impact factor: 2.433

3.  Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.

Authors:  Ming-Hui Xue; Guang-Yan Li; Xin-Jun Wu; Chao-Xian Zhang; Cai-Feng Zhang; Kong-Xi Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Environmental exposure to benzene, micronucleus formation and polymorphisms in DNA-repair genes: a pilot study.

Authors:  Sabrina Angelini; Francesca Maffei; Justo Lorenzo Bermejo; Gloria Ravegnini; Domenica L'insalata; Giorgio Cantelli-Forti; Francesco Saverio Violante; Patrizia Hrelia
Journal:  Mutat Res       Date:  2012-01-11       Impact factor: 2.433

5.  Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotype to Gastric Cancer Risk in Taiwan.

Authors:  Hong-Xue Ji; Wen-Shin Chang; Chia-Wen Tsai; Ju-Yu Wang; Nai-Kuei Huang; An-Sheng Lee; Ming-Yi Shen; Wei-Yu Chen; Yao-Chang Chiang; Tzu-Ching Shih; Chin-Mu Hsu; Da-Tian Bau
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

6.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 7.  Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.

Authors:  Gloria Ravegnini; Giulia Sammarini; Sabrina Angelini; Patrizia Hrelia
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-05-17       Impact factor: 4.481

8.  Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.

Authors:  Sabrina Angelini; Gloria Ravegnini; Margherita Nannini; Justo Lorenzo Bermejo; Muriel Musti; Maria A Pantaleo; Elena Fumagalli; Nicola Venturoli; Elena Palassini; Nicola Consolini; Paolo G Casali; Guido Biasco; Patrizia Hrelia
Journal:  Eur J Hum Genet       Date:  2014-09-17       Impact factor: 4.246

9.  XPA-mediated regulation of global nucleotide excision repair by ATR Is p53-dependent and occurs primarily in S-phase.

Authors:  Zhengke Li; Phillip R Musich; Moises A Serrano; Zhiping Dong; Yue Zou
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

10.  Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.

Authors:  Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more
  8 in total

Review 1.  Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.

Authors:  Gloria Ravegnini; Giulia Sammarini; Margherita Nannini; Maria A Pantaleo; Guido Biasco; Patrizia Hrelia; Sabrina Angelini
Journal:  Autophagy       Date:  2017-01-05       Impact factor: 16.016

2.  Role of Xeroderma Pigmentosum Group D in Cell Cycle and Apoptosis in Cutaneous Squamous Cell Carcinoma A431 Cells.

Authors:  Ou-Gen Liu; Xiao-Yan Xiong; Chun-Ming Li; Xian-Sheng Zhou; Si-Si Li
Journal:  Med Sci Monit       Date:  2018-01-24

3.  Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.

Authors:  Ruoxin Zhang; Ming Jia; Huijing Xue; Yuan Xu; Mengyun Wang; Meiling Zhu; Menghong Sun; Jianhua Chang; Qingyi Wei
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

4.  The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility.

Authors:  Gloria Ravegnini; César Serrano; Vittorio Simeon; Giulia Sammarini; Margherita Nannini; Erica Roversi; Milena Urbini; Fabrizio Ferrè; Riccardo Ricci; Giuseppe Tarantino; Maria A Pantaleo; Patrizia Hrelia; Sabrina Angelini
Journal:  Epigenetics       Date:  2019-04-13       Impact factor: 4.528

Review 5.  Somatic pharmacogenomics of gastrointestinal stromal tumor.

Authors:  Gloria Ravegnini; Patrizia Hrelia; Sabrina Angelini
Journal:  Cancer Drug Resist       Date:  2019-03-19

6.  Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy.

Authors:  Xiaoyun Hu; Wenyan Qin; Shanqiong Li; Miao He; Yilin Wang; Shu Guan; Haishan Zhao; Weifan Yao; Minjie Wei; Mingyan Liu; Huizhe Wu
Journal:  Cancer Manag Res       Date:  2018-12-27       Impact factor: 3.989

Review 7.  XPA: DNA Repair Protein of Significant Clinical Importance.

Authors:  Lucia Borszéková Pulzová; Thomas A Ward; Miroslav Chovanec
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

8.  Comprehensive assessment of the association between XPC rs2228000 and cancer susceptibility based on 26835 cancer cases and 37069 controls.

Authors:  Yingqi Dai; Zhonghua Song; Jinqing Zhang; Wei Gao
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.